LimmaTech Biologics is very pleased to announce that the paper on the “Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial” received an award from The Swiss Society for Infectious Diseases in the category “clinical research in infectious diseases”. We like to thank all the people involved in this achievement.

Dr Amir Faridmoayer to present.